Neoadjuvant mitomycin C showed a favorable safety profile with mild to moderate side effects, including hematuria, dysuria, and itchy scalp. The trial did not show significant improvement in 12-month ...
Clinical outcomes of neoadjuvant intravesical mitomycin-C therapy administered immediately prior to TURBT in NMIBC: Over three years of follow-up data from a randomized phase II trial. This is an ASCO ...
The FDA has approved mitomycin intravesical solution (Zusduri, UroGen Pharma) for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The intravesical mitomycin formulation is ...
PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...
Neoadjuvant mitomycin C prior to TURBT reduced recurrence risk by 77%, possibly by preventing free-floating cancer cells dislodged during surgery from reimplanting and by increasing local exposure at ...
Influence of low-coverage whole-genome sequencing–based urinary tumor fraction and chromosomal instability on recurrence risk stratification in systemic immunotherapy-treated non–muscle–invasive ...
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...
The FDA has granted approval to UGN-102 for use in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer. The U.S. Food and Drug Administration has approved UGN-102 (mitomycin ...
ZUSDURI shows promising long-term efficacy in treating low-grade intermediate-risk bladder cancer, maintaining event-free survival in patients. UroGen Pharma Ltd. announced findings published in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results